Angiotensin 2 Type 1 Receptor Antagonists [MoA]

Known as: Angiotensin II Type 1 Receptor Antagonists, Angiotensin 2 Type 1 Receptor Antagonists, Angiotensin II Type I Receptor Blockers 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A new treatment for heart failure (HF) combining angiotensin 2 type 1 receptor blockade with inhibition of the widespread… (More)
Is this relevant?
2015
2015
HYPOTHESIS This study determined the parameters for predicting the clinical effects of eplerenone (Ep) add-on therapy on blood… (More)
Is this relevant?
2013
2013
Heart failure is now the most common condition that leads to hospital admission in industrialized nations. Although the overall… (More)
Is this relevant?
Review
2012
Review
2012
The metabolic syndrome affects 30% of the US population with increasing prevalence. In this paper, we explore the relationship… (More)
Is this relevant?
2012
2012
BACKGROUND Both angiotensin II type I receptor blockers (ARBs) and calcium channel blockers (CCBs) are widely used… (More)
  • table 1
  • table 2
  • table 3
  • table 3
  • table 4
Is this relevant?
Review
2007
Review
2007
The aim of the present work was to review published studies investigating the dose-related efficacy on blood pressure (BP) of… (More)
Is this relevant?
2004
2004
Anemia is one of the most serious complications in patients on dialysis. Erythropoietin improves the anemia. However… (More)
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table I
Is this relevant?
2003
2003
OBJECTIVE Angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type I receptor blockers (ARB) prevent cardiac… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2002
2002
Chronic heart failure is one of the most serious cardiac problems encountered in clinical practice. Modulation of the renin… (More)
Is this relevant?
2002
2002
Angiotensin II type I receptor antagonists (ARAs) have been tested in two large randomized trials, Evaluation of Losartan in the… (More)
Is this relevant?